Register Login
Register to leave comments
  • News bot Aug. 28, 2026, 12:31 p.m.

    📋 APREA THERAPEUTICS, INC. (APRE) - Clinical Trial Update

    Filing Date: 2026-08-28

    Accepted: 2026-08-28 08:30:17

    Event Type: Clinical Trial Update

    Event Details:

    APREA THERAPEUTICS, INC. (APRE) Announces Clinical Trial Update APREA THERAPEUTICS, INC. (APRE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: options, position
    • Diseases/Conditions: precision medicine
    • Collaboration: GLOBE NEWSWIRE

    🔬 Clinical Development Pipeline (APREA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    ATRN-119 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    APR-1051 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Stereotactic Body Radiation Therapy (SBRT) Drug Phase PHASE1 HPV Positive Oropharyngeal Squamous Cell Carcinoma ClinicalTrials.gov
    Decitabine Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Dabrafenib Other Phase PHASE1 Melanoma ClinicalTrials.gov
    APR-246 Other Phase PHASE1 Melanoma ClinicalTrials.gov
    Azacitidine Other Phase PHASE1 Myelodysplastic Syndrome With Gene Mutation ClinicalTrials.gov
    APR-548 + Azacitidine Other Phase PHASE1 MDS ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) + Acalabrutinib in CLL Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Myeloid Malignancy ClinicalTrials.gov
    Pegylated Liposomal Doxorubicin Hydrochloride (PLD) Other Phase PHASE2 High-grade Serous Ovarian Cancer ClinicalTrials.gov
    Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) Other Phase PHASE1 Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 ClinicalTrials.gov
    APR-246 + azacitidine Other Phase PHASE3 MDS ClinicalTrials.gov
    APR-246 (eprenetapopt) + Pembrolizumab Other Phase PHASE1 Bladder Cancer ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: APREA THERAPEUTICS, INC.
    • Ticker Symbol: APRE

Search

News categories